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Abstract
Background. There are conflicting results on the role of cobalamin and folate for epidemiology and carcinogenesis in
colorectal cancer patients and the need of supplementation for prevention of chemotherapy toxicity.
Patients and methods. Serum cobalamin, folate, and homocysteine were analysed before and during the treatment of
93 patients with advanced colorectal cancer (ACRC) with first-line chemotherapy treatment. This cohort was compared
with a healthy control group of 224 individuals.
Results. Patients with ACRC had similar cobalamin, folate, and homocysteine values as the healthy control group. There
were no correlations between serum cobalamin, folate, and homocysteine values and objective response. There were no
correlations to anaemia or other severe toxicity for cobalamin and homocysteine. A total of 12 patients had folate deficiency,
and 10 of those suffered from severe toxicity (grade 3 or more). All patients had markedly increased folate values after 2
months of treatment. Folate and homocysteine did not predict patient outcome; however, patients with subclinically low
cobalamin values ( B300 pmol/L) had significant better overall survival and time to progression than patients with normal or
high cobalamin values.
Conclusion. Patients with ACRC seem to have fairly adequate cobalamin and folate status before and during chemotherapy
treatment. This study indicates that ACRC patients receiving chemotherapy do not need supplementation with vitamin B12
and folate. A minor portion of the patients had folate deficiency, and most of those patients had severe toxicity. Patients with
subclinically low cobalamin values had surprisingly better survival.
Key words: Chemotherapy, cobalamin, colorectal cancer, folate, homocysteine
Introduction
Vitamin B12 deficiency may cause genetic instability,
and folate is essential for regenerating methionine,
the methyl donor for DNA methylation, and for
producing the metabolites for DNA synthesis. Inade-
quate availability of folate may contribute to abnorm-
alitiesinDNAsynthesisorrepair,eitherofwhichmay
influence colon carcinogenesis. There are several
studies which indicate that people with deficiency of
vitamin B12 and folate have an increased risk for
developing colorectal cancer (1 4). There are also
cohort studies indicating decreased risk for colorectal
cancer among patients with high intake of folate,
dietary or as supplementation (5). Other authors do
not find these correlations, and there might be a
theoretical risk of potentiating the progression of an
already established early neoplastic clone (e.g. color-
ectal adenoma) (6).
Pemetrexed (Alimta†) is a novel multi-target
antifolate that inhibits several enzymes involved in
DNA synthesis such as thymidylate synthase (TS),
dihydrofolate reductase (DHFR), and glycinamide
ribonucleotide formyltransferase (GARFT). Early
studies showed a severe toxicity profile, but further
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toxicity. The reason for that was assumed to be
folate supplementation in flour (7). Therefore Alimta
is given together with folate and vitamin B12
supplementation (8).
In a randomized, prospective, phase III trial
(Nordic VI), irinotecan (Campto†*topoisomerase
1 blocker) in combination with either bolus 5
Fluorouracil (5-FU)/leucovorin or bolus/infused 5-
FU/leucovorin was compared in patients with meta-
static colorectal cancer (9). These two schedules
(FLIRI versus Lv5FU2-IRI) resulted in the same
progression-free survival and overall survival, being
the primary end-points, although the Lv5FU2-IRI
schedule resulted in slightly more objective re-
sponses and slightly less toxicity. We have retro-
spectively analysed the patients from the two largest
hospitals in the study for various clinical and other
predictors of toxicity.
The aim of this study was to compare serum
cobalamin, folate, and homocysteine values of
ACRC patients before and during chemotherapy
treatment, to detect any possible deficiency and to
relate that to outcome and toxicity in a retrospective
analysis.
Material and methods
Patients
From June 2001 to March 2004, 567 patients with
non-resectable metastatic disease from histologically
confirmed colorectal adenocarcinoma were inclu-
ded in a Nordic multi-centre study, the Nordic VI
study. At two major hospitals, Uppsala and Stock-
holm, Sweden, 93 patients were included for serum
sampling of cobalamin, folate, and homocysteine.
This sub-study with B12, folate, and homocysteine
status among ACRC patients was compared with a
previously performed study on healthy volunteers in
the same county with median age of 77 years (10).
No prior chemotherapy other than adjuvant
5-FU-based chemotherapy completed at least
6 months before the study entry was allowed. All
patients should have measurable disease according
to the response evaluation criteria in solid tumours
(RECIST) (11), age between 19 and 76 years, WHO
performance status of 0 to 2, and adequate labora-
tory values. The upper serum bilirubin level should
beB1.25 the upper normal limit (UNL) (1.5 if
liver metastases).
The study was approved by the ethical com-
mittees at each site. All patients provided infor-
med consent for the clinical study and for this
sub-study.
Treatment
The patients were treated in a multi-centre phase III
study comparing two different fluorouracil (5-FU)
schedules in combination with irinotecan. The
patients were randomly assigned to receive irinote-
can with the Nordic 5FU/Leucovorin (FLv) sche-
dule (12) or the Lv5FU2 schedule (13). The FLIRI
regimen (14) consisted of irinotecan (Campto†)
180 mg/m
2 (initially 210 mg/m
2) as a 60-minute
intravenous (i.v.) infusion on day 1, followed im-
mediately by 5-FU 500 mg/m
2 as a bolus (B5 min)
injection, followed 30 40 minutes later by Folinic
acid (FA) 60 mg/m
2 i.v. bolus. The 5-FU/FA
administrations were repeated on day 2. The
Lv5FU2-IRI regimen (15) consisted of irinotecan
180 mg/m
2 on day 1, followed by FA 200 mg/m
2 as a
2-hour infusion, a 5-FU bolus of 400 mg/m
2,
followed by a 600 mg/m
2 22-hour infusion. The 5-
FU/FA administrations were repeated on day 2. All
treatments were repeated every 2 weeks until disease
progression or unacceptable toxicity. A 20% reduc-
tion in dose of irinotecan and 5-FU was made in
case of grade 3 4 haematological and non-haemato-
logical toxicities. A second 20% reduction was also
allowed if toxicities remained. Treatments were
delayed for up to 2 weeks if the haematological
and gastrointestinal toxicities had not resumed for
grade 1 at the time of next cycle.
Concomitant medication included subcutaneous
atropine 0.25 mg,administered for cholinergic symp-
toms,oralloperamide2mgfordiarrhoea,and,incase
of fever or severe neutropenia, a prophylactic broad-
spectrum oral antibiotic (ciprofloxacin) was to be
administered. Patients with febrile neutropenia were
hospitalized to receive i.v. antibiotics. The patients
Table I. Patient characteristics.
Age, years Median (range) 63 (42 76)
Colon 57
Rectum 36
Sex Male 59
Female 34
WHO 0 72
11 8
23
Primary tumour resected Yes 72
No 17
Missing data 4
Adjuvant treatment Yes 13
No 80
Haemoglobin, g/L Mean (range) 127 (94 158)
Median 128
Objective response Complete remission 5
Partial remission 36
Stable disease 35
Progressive disease 12
Not evaluable 5
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mide and selective serotonin antagonists (5-HT3)
blockers.
Response and toxicity evaluation
Tumour response was assessed according to RE-
CIST criteria (11). Toxicity was evaluated according
to the National Cancer Institute common toxicity
criteria, version 2 (16). The information prospec-
tively recorded in the case record forms was used.
Serum sampling and measurements
Serum for cobalamin, folate, and homocysteine
analyseswas taken at base-line and prior to the fourth
cycle, i.e.at2monthsoftreatment.Immediatelyafter
sampling, aliquots were frozen at  208C for later
analyses. The results of the analyses were unknown
for the treating physicians. Serum cobalamin (re-
agent: 6C09), folate (reagent: 7K60-32), and homo-
cysteine (reagent: FHER100) were analysed on an
ArchitectCi8200(AbbottLaboratories,AbbottPark,
IL, USA) and reported using SI units. The total
coefficients of variation were 7.0% at 480 pmol/L for
cobalamin, 2.6% at 28 nmol/L for folate, and 2.7% at
29.3 mmol/L for homocysteine. The same measure-
ment procedure was performed for the historical
control of the healthy population.
Statistical analyses
Comparisons of proportion between groups were
performed by chi-square analyses. Correlations were
studied with Spearman’s rank correlation test. Sur-
vival curves were drawn according to Kaplan-Meier.
Results
Patient homocysteine values did not correlate to
patient outcomes, i.e. objective response (OR), time
to progression (TTP), overall survival (OS), anae-
mia, or chemotherapy toxicity (data not shown).
There were only two patients with cobalamin
values lower than reference. Those 2 patients and
33patientswith subclinically lowvalues(B300pmol/
L) did not have more toxicity than patients with
higher values (approximately 50% of the patients
suffered from at least one reported grade 3 or more
toxicity). There was no correlation between cobala-
min values and objective response; however, patients
with values B300 pmol/L at base-line had better OS
(P 0.0002) (Figure 1) and TTP (P 0.03) than
patients with higher values. There were only modest
changes of the patients’ cobalamin values after
2 months of treatment.
A total of 12 patients (13%) had folate deficiency
before the start of the chemotherapy treatment, and,
of those, 10 patients (83%) suffered from grade 3
toxicity or more. Those 10 patients had the same
toxic profile as other patients with severe toxicity. All
patients had markedly increased folate values after 2
months of chemotherapy treatment. There were no
correlations with patients’ folate status and OR,
TTP, or OS.
None of these markers correlated to haemoglo-
bin value or performance status.
The patients’ cobalamin, folate, and homocys-
teine values were almost equal to a previously
performed study with a healthy control group of
224 individuals from the same county (Table III),
although the controlgroupwas slightlyolder(median
77 years).
Discussion
In the current study, we examined serum levels of
cobalamin, folate, and homocysteine in patients with
ACRC, before and after 2 months of treatment.
There are, going through the literature, conflict-
ing results on how to interpret the importance of the
endogenous levels of B12, folate, and homocysteine
in association with ACRC development, as discussed
in the introduction, but also whether or not these
levels should be taken into account when it comes to
treatment.
Table II. The results of the analyses.
n Mean Median Range 95% CI
S-Cobalamin base-line, pmol/L 81 421 368 37 1476 134 853
S-Cobalamin after 2 months, pmol/L 67 409 354 13 1480 39 1123
S-Folate at base-line, nmol/L 93 10.0 7.6 1.0 45.3 3.0 30.4
S-Folate after 2 months, nmol/L 71 28.4 28.8 10.2 45.5 16.8 38.6
S-Homocysteine at base-line, mmol/L 93 19.3 17.8 6.6 43.5 9.6 36.2
S-Homocysteine after 2 months, mmol/L 73 16.6 13.5 0.6 230.0 8.2 21.4
CI confidence intervals.
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treatment of patients with ACRC and remains an
integral component of modern combination regi-
mens. Antifolate chemotherapy agents such as 5-FU
reduce proliferation of neoplastic cells by inhibiting
DNA synthesis. 5-FU interferes with the folate
metabolism by inhibition of thymidylate synthetase.
Interrupting the action of this enzyme blocks synth-
esis of the pyrimidine thymidine, which is a nuc-
leotide required for DNA replication. Thymidylate
synthase methylates deoxyuridine monophoshate
(dUMP) into thymidine monophosphate (dTMP).
It has been postulated that measuring the levels
of some of the key components (B12, folate, and
homocysteine) in the folate metabolism would be of
importance for tailored treatments for our patients.
A number of clinical studies have illustrated that
pretreatment levels of folate and homocysteine are
predictive for both tumour response and toxicity (low
folate levels are associated with increased toxicity) in
patients treated with either thymidylate synthase
(TS) inhibitors or folate antagonists (8,17,18). Pre-
vious murine studies have indicated that folate levels
may predict for the cytotoxic efficacy of 5-FU (19). It
has also been shown that an increased amount of
exogenous folate leads to enhanced TS inhibition
(20).
On the other hand, two recent clinical studies
have indicated a relationship between dietary folate
intake and fluoropyrimidine toxicity (21,22). In
one study, 86 Canadian patients receiving adjuvant
5-FU and leucovorin were prospectively assessed
for biomarkers of folate metabolism. Multivariate
analyses identified base-line serum folate as an
independent positive predictor for grade 3 4 toxicity.
A similar result was found in a study of capecitabine
monotherapy, in which patients with higher base-line
levels of serum folate had a significantly increased
incidence of toxic events (23).
These conflicting findings have been debated,
and one explanation may be the different mechan-
isms of action of the antifolates. The antifolates
compete with naturally occurring folate for active
moieties on folate-dependent enzymes. Depletion in
the level of intracellular folate will therefore lead to
increased toxicity. Furthermore, the level of intra-
cellular folate feeds back to inhibit the polyglutama-
tion of antifolates, limiting toxicity. This, however,
remains to be further elucidated.
Inthisstudywehaveshownthatbase-linelevelsof
B12, folate, and homocysteine for a patient popula-
tion with advanced ACRC (n 93) were almost the
same as for a previous performed cohort study of 224
healthy individuals from the same county. Our study
also reveals that most individuals in an unselected
population with advanced ACRC, in spite of their
possible intestinal problems and earlier operations,
still have normal levels of serum cobalamin, folate,
and homocysteine. Cobalamin deficiency is rare in
this population, and this is most likely explained by
the fact that the endogenous stores of B12 last for
severalyears,andthecourseofthediseasenormallyis
shorter. None of the two patients who had B12 levels
below the reference experienced increased toxicity.
On the contrary, 10 out of 12 patients who suffered
from grade 3 4 toxicity had folate levels below the
reference before start of treatment. It is somewhat
doubtful that this is related to the subclinically low
levels of folate before the start of treatment in this
population, given the excess amount of folate admi-
nistered as part of the treatment. A partial explana-
tion might be the rate-limiting transport mechanism
from extra- to intracellular space carried out by
reduced folate carriers. Another explanation might
be that the patients with the lowest levels of folate
mightbetheoneswiththemostadvanceddiseaseand
therefore the most undernourished.
Interestingly in this study, patients with sub-
clinically low cobalamin values had superior overall
survival and time to progression than did patients
with higher values. It is not possible to offer a good
explanation for this, but it might reflect a worse
outcome among patients with more liver metas-
tases. It is known that patients with liver injuries
can have increased serum cobalamin values. The-
oretically, patients with lower cobalamin values
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Figure 1. Overall survival curve according to base-line B12 status.
Table III. Healthy controls (n 224).
Mean Median 95% CI
S-Cobalamin, pmol/L 376 302 342 410
S-Folate, nmol/L 11.5 8.8 10.2 12.8
S-Homocysteine, mmol/L 16.8 14.7 15.9 17.8
CI confidence intervals.
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tion etc. It could also be explained with a statistical
mass effect.
Based on the results from this study, it is not
clinically relevant to tailor treatment for individual
ACRC patients based on B12, folate, or homocys-
teine levels. Most likely the individual patients gain
more if we tailor treatment with respect to more
established predictive markers for toxicity and treat-
ment effect, like dihydropyrimidine dehydrogenase
(DPD), TS, and Thymidine phosphorylase (TP)
levels when treating with antifolates.
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